1. Generics Bulletin
  2. >>Products

Russia’s Generium Announces First Biosimilar Of Soliris

 
• By Penelope MacRae

Russia’s Generium has announced its launch of the first biosimilar version of Alexion’s blockbuster orphan-disease drug Soliris, one of the most expensive prescription medicines in the world.

RussiaMap
Generium’s Russian Launch Is A Global First • Source: Shutterstock

Orphan-disease drug company Generium JSC, owned by Russian billionaire Viktor Kharitonin, says it has launched the first biosimilar of Alexion’s blockbuster medicine Soliris (eculizumab) to treat two extremely rare and life-threatening blood diseases. The Russian biosimilar is branded under the name of Elizaria and was developed using a platform created by Switzerland-based cell-line development specialist Selexis SA.

“We’re the first company in the world to develop and market a biosimilar of eculizumab

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”